Cosgun Yasemin, Emanet Nergis, Kamiloglu Ayten Öz, Grage-Griebenow Evelin, Hohensee Susann, Saschenbrecker Sandra, Steinhagen Katja, Korukluoglu Gulay
National Arboviruses and Viral Zoonotic Diseases Laboratory, Microbiology Reference Laboratories Department, Public Health General Directorate of Turkey, Ankara 06100, Turkey.
Virology Unit, Department of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey.
Vaccines (Basel). 2023 Jan 18;11(2):216. doi: 10.3390/vaccines11020216.
While most approved vaccines are based on the viral spike protein or its immunogenic regions, inactivated whole-virion vaccines (e.g., CoronaVac) contain additional antigens that may enhance protection. This study analyzes short-term humoral responses against the SARS-CoV-2 spike (S1) and nucleocapsid (NCP) protein in 50 Turkish adults without previous SARS-CoV-2 infection after CoronaVac immunization. Samples were collected before vaccination (t0), 28-29 days after the first vaccine dose and prior to the second dose (t1), as well as 14-15 days after the second dose (t2). Anti-S1 IgG and IgA as well as anti-NCP IgG were quantified using ELISA. At t1, seroconversion rates for anti-S1 IgG, anti-S1 IgA and anti-NCP IgG were 30.0%, 28.0% and 4.0%, respectively, increasing significantly to 98.0%, 78.0% and 40.0% at t2. The anti-NCP IgG median (t2) was below the positivity cut-off, while anti-S1 IgG and IgA medians were positive. Anti-S1 IgG levels strongly correlated with anti-S1 IgA (r = 0.767, < 0.001) and anti-NCP IgG (r = 0.683, < 0.001). In conclusion, two CoronaVac doses induced significant increases in antibodies against S1 and NCP. Despite strong correlations between the antibody concentrations, the median levels and seroconversion rates of S1-specific responses exceed those of NCP-specific responses as early as two weeks after the second vaccine dose.
虽然大多数获批的疫苗是基于病毒刺突蛋白或其免疫原性区域，但灭活全病毒疫苗（如科兴新冠疫苗）含有可能增强保护作用的其他抗原。本研究分析了50名既往未感染过严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的土耳其成年人在接种科兴新冠疫苗后的短期体液免疫反应，针对SARS-CoV-2刺突蛋白（S1）和核衣壳蛋白（NCP）。在接种疫苗前（t0）、第一剂疫苗接种后28 - 29天且在第二剂疫苗接种前（t1）以及第二剂疫苗接种后14 - 15天（t2）采集样本。使用酶联免疫吸附测定（ELISA）对抗S1 IgG和IgA以及抗NCP IgG进行定量。在t1时，抗S1 IgG、抗S1 IgA和抗NCP IgG的血清转化率分别为30.0%、28.0%和4.0%，在t2时显著增加至98.0%、78.0%和40.0%。抗NCP IgG中位数（t2）低于阳性临界值，而抗S1 IgG和IgA中位数为阳性。抗S1 IgG水平与抗S1 IgA（r = 0.767，P < 0.001）和抗NCP IgG（r = 0.683，P < 0.001）密切相关。总之，两剂科兴新冠疫苗诱导了针对S1和NCP的抗体显著增加。尽管抗体浓度之间存在强相关性，但早在第二剂疫苗接种后两周，S1特异性反应的中位数水平和血清转化率就超过了NCP特异性反应。
Zotero 插件